Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program
A high BMI did not significantly affect efficacy and safety outcomes of etrasimod (NCT03945188; NCT03996369).
Authors
- Gokul Pradeep
- Remo Panaccione (ORCID: https://orcid.org/0000-0002-5247-940X)
- Raymond K. Cross (ORCID: https://orcid.org/0000-0001-9766-5196)
- Wojciech Niezychowski
- Martina Goetsch
- Andrés Yarur (ORCID: https://orcid.org/0000-0003-2293-5555)
- Neilanjan Nandi (ORCID: https://orcid.org/0000-0001-7624-3314)
- Catherine M. Crosby (ORCID: https://orcid.org/0000-0002-8912-8179)
- Millie D. Long (ORCID: https://orcid.org/0000-0001-5983-2758)
- Joana Torres (ORCID: https://orcid.org/0000-0003-2895-5821)
- Arcangelo M. Abbatemarco
- David Blanco
- Joseph Wu (ORCID: https://orcid.org/0009-0006-3464-2556)
Institutions
- University of North Carolina at Chapel Hill (US)
- Cedars-Sinai Medical Center (US)
- Mercy Medical Center (US)
- University of Lisbon (PT)
- University of Calgary (CA)
- Pfizer (United States) (US)
- Pfizer (Switzerland) (CH)
- Hospital da Luz (PT)
- Hospital Beatriz Ângelo (PT)
- Pfizer (India) (IN)
- University of Pennsylvania (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-01-29
- DOI
- https://doi.org/10.14309/ajg.0000000000003330
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Pfizer